← Back to Search

Fan Therapy for COPD

N/A
Recruiting
Led By Dennis Jensen, PhD
Research Sponsored by McGill University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 serial dynamic inspiratory capacity maneuvers for each minute of the 4-minute constant rate treadmill test.

Summary

This trial will explore how fan-to-face therapy helps with breathlessness during exercise in people with cardiorespiratory disease.

Who is the study for?
This trial is for people who feel breathless during exercise despite treatment, with a BMI between 18.5 and 35, cleared for physical activity by a doctor, and diagnosed with cardiopulmonary diseases like COPD or heart failure. It's not for those who've changed medication recently or had an exacerbation/hospitalization in the last six weeks.
What is being tested?
The study tests if blowing cool air on the face using Honeywell HT-900 Turbo Force Air Circulator can relieve shortness of breath during constant-rate exercise in individuals with cardiorespiratory disease. The aim is to understand how this simple intervention works physiologically.
What are the potential side effects?
Since the intervention involves non-invasive use of a fan to circulate air, there are no direct medicinal side effects expected from this trial. However, participants should be monitored for any discomfort or adverse reactions related to airflow exposure during exercise.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 serial dynamic inspiratory capacity maneuvers for each minute of the 4-minute constant rate treadmill test.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 serial dynamic inspiratory capacity maneuvers for each minute of the 4-minute constant rate treadmill test. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Borg modified 0-10 category ratio scale for breathlessness intensity
Secondary study objectives
Cardiopulmonary exercise test (3-minute constant rate) physiological response (oxygen saturation)
Cardiopulmonary exercise test (4-minute constant rate) physiological response (heart rate)
Cardiopulmonary exercise test (4-minute constant rate) physiological response (operating lung volumes)
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Fan-to-faceExperimental Treatment1 Intervention
The participants will complete a 4-minute constant work rate treadmill test with a basic, portable fan placed in front of the face. The fan will be placed at a location to target the second and third branches of the trigeminal nerve and will be placed a distance chosen by the participant so that the airflow speed is comfortable.
Group II: No fanActive Control1 Intervention
The participants will complete a 4-minute constant work rate treadmill test with no fan.
Group III: Fan-to-legPlacebo Group1 Intervention
The participants will complete a 4-minute constant work rate treadmill test with a basic, portable fan placed in front of the face. The fan will be placed at a location to target the second and third branches of the trigeminal nerve and will be placed a distance chosen by the participant so that the airflow speed is comfortable.

Find a Location

Who is running the clinical trial?

McGill UniversityLead Sponsor
411 Previous Clinical Trials
1,018,475 Total Patients Enrolled
Dennis Jensen, PhDPrincipal InvestigatorMcGill University
2 Previous Clinical Trials
88 Total Patients Enrolled

Media Library

Fan-to-face Clinical Trial Eligibility Overview. Trial Name: NCT05659550 — N/A
Chronic Obstructive Pulmonary Disease Research Study Groups: No fan, Fan-to-face, Fan-to-leg
Chronic Obstructive Pulmonary Disease Clinical Trial 2023: Fan-to-face Highlights & Side Effects. Trial Name: NCT05659550 — N/A
Fan-to-face 2023 Treatment Timeline for Medical Study. Trial Name: NCT05659550 — N/A
~0 spots leftby Nov 2024